Price
No data yet.
Social Signal Score
Revenue
$1.77B+104.24%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Peter Halling
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 2,721
- Beta
- 0.71
- Country
- DK
- Piotroski score
- 7 / 9 (Strong)
- Altman Z-score
- 13.54
Financials
Revenue
$1.77B+104.2%Net Income
$437.45MEBITDA
$654.68M+1263.9%Free Cash Flow
$714.74M+1601.8%EPS (diluted)
$1.95Shares Outstanding (diluted)
221.58M+5.5%Operating Expenses
$658.68MCash & Debt
$1.55BReturn of Capital
$355.37MDividend per Share
$0.24Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $6.30B | $1.19B | $5.41 |
| 2024 | $5.54B | $815.00M | $3.68 |
| 2023 | $4.82B | $486.00M | $2.20 |
| 2022 | $4.51B | $335.00M | $1.52 |
| 2021 | $3.92B | $219.00M | $1.00 |
| 2020 | $3.49B | $25.00M | $0.11 |
| 2019 | $3.27B | $-50.00M | $-0.23 |
| 2018 | $2.92B | $-170.00M | $-0.78 |
| 2017 | $2.91B | $-158.00M | $-0.80 |
| 2016 | $3.00B | $270.00M | $1.38 |
| 2015 | $2.57B | $344.00M | $1.77 |
| 2014 | $2.43B | $181.00M | $0.94 |
| 2013 | $2.24B | $61.00M | $0.32 |
| 2012 | $2.35B | $209.00M | $1.07 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from AKBLF's reported EPS growth of 13.3% a year over 13 years.
- EPS in 5 years
- $10.07
- Implied price
- $422.75
- Return from $37.91
- 62.0% a year
To earn 15.0% a year on these assumptions you'd need to buy at $210.18 — today's price is already 82.0% below that.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 30 | 36 | 42 | 48 | 54 |
|---|---|---|---|---|---|
| 3.3% | 38.1% | 43.2% | 47.7% | 51.7% | 55.3% |
| 8.3% | 44.8% | 50.1% | 54.8% | 59.0% | 62.8% |
| 13.3% | 51.4% | 57.1% | 62.0% | 66.4% | 70.3% |
| 18.3% | 58.1% | 64.0% | 69.1% | 73.7% | 77.8% |
| 23.3% | 64.8% | 70.9% | 76.3% | 81.0% | 85.4% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
120Social Signal Score
Mentions (1)
- Newsseekingalpha.com·5h ago·Positive
ALK-Abelló A/S (AKBLF) Q2 2026 Earnings Call Transcript ALK-Abelló A/S (AKBLF) Q2 2026 Earnings Call Transcript
View source ↗
Earnings
Tue, Nov 17(in 3 months)
Consensus estimate $0.26 per share
Typical surprise +0.1% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 20$0.23 vs $0.23beat
- Mon, May 4$0.31 vs $0.26beat
- Fri, Feb 20$0.19 vs $0.20miss
- Wed, Nov 12$0.22 vs $0.16beat
- Thu, Aug 21$0.19 vs $0.20miss
- Tue, May 6$0.23 vs $0.20beat
Estimates and results for AKBLF via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.